ACHV

Achieve Life Sciences, Inc. (NASDAQ:ACHV) is a clinical-stage pharmaceutical company founded in 1995 and based in Vancouver, Canada. The company focuses on developing cytisinicline, a plant-based alkaloid derived from the golden rain tree, as a smoking cessation and nicotine addiction treatment. After decades of development, Achieve is preparing to submit its New Drug Application (NDA) to the FDA in mid-2025, positioning itself to potentially launch the first new FDA-approved nicotine dependence treatment in nearly 20 years.